Revelation Biosciences (FRA:56U0) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Debt-to-Asset?

Revelation Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Revelation Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Revelation Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €13.53 Mil. Revelation Biosciences's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

Revelation Biosciences Debt-to-Asset Historical Data

The historical data trend for Revelation Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Debt-to-Asset Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.01

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Revelation Biosciences's Debt-to-Asset

For the Biotechnology subindustry, Revelation Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revelation Biosciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's Debt-to-Asset falls into.

Revelation Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Revelation Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	11.199
	=	0.00

Revelation Biosciences's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	13.526
	=	0.00

Revelation Biosciences (FRA:56U0) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Revelation Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

REVB:USA 56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines